Suzetrigine for Vaso-Occlusive Pain in Sickle Cell Disease: A Three-Patient Case Series
Orthopedic Reviews · 22.05.2026 · 18
DOI: 10.52965/001c.162149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Orthopedic Reviews, online erschienen am 22.05.2026. Verfasst von Sami Joudeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas Health Science Center at Houston. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive crises and chronic pain, often requiring multimodal analgesia that frequently includes opioids. Given the risks associated with long-term opioid therapy, there is a growing need for effective non-opioid alternatives. Suzetrigine, a selective NaV1.8 sodium channel inhibitor, represents a novel analgesic approach targeting peripheral nociceptive signaling.
Methods
We present a case series of three patients with sickle cell-related pain treated with suzetrigine as part of a multimodal pain management strategy. The cohort included one patient with sickle cell trait (HbAS), one with hemoglobin SC disease, and one with hemoglobin SS disease. Clinical outcomes, including pain control, healthcare utilization, and medication use, were evaluated.
Results
Two of three patients reported subjective improvement in pain control with suzetrigine, including reduced reliance on opioid medications and no emergency department visits or hospitalizations during the observation period. Both patients were on minimal opioid therapy. In contrast, the third patient, who was maintained on chronic opioid therapy, did not experience improvement and required hospitalization for pain management. No adverse effects related to suzetrigine were observed in any patient.
Conclusion
Suzetrigine may be a non-opioid adjunct for managing sickle cell-related pain, particularly in opioid-naïve or opioid-intolerant patients. However, its efficacy may be limited in opioid-tolerant individuals. Larger studies are needed to better define its role in the management of vaso-occlusive pain and chronic pain in SCD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The University of Texas Health Science Center at Houston.
- Johns Hopkins Medicine.
Zitieren
APA
Joudeh, S., Moore, D., Hasoon, J., Robinson, C. L., Idowu, M., & Oso, T. (2026). Suzetrigine for Vaso-Occlusive Pain in Sickle Cell Disease: A Three-Patient Case Series. Orthopedic Reviews, 18. https://doi.org/10.52965/001c.162149
Vancouver
Joudeh S, Moore D, Hasoon J, Robinson CL, Idowu M, Oso T. Suzetrigine for Vaso-Occlusive Pain in Sickle Cell Disease: A Three-Patient Case Series. Orthopedic Reviews. 2026;18. doi:10.52965/001c.162149
BibTeX
@article{Joudeh2026,
author = {Joudeh, Sami and Moore, Darayon and Hasoon, Jamal and Robinson, Christopher L and Idowu, Modupe and Oso, Tolulope},
title = {Suzetrigine for Vaso-Occlusive Pain in Sickle Cell Disease: A Three-Patient Case Series},
journal = {Orthopedic Reviews},
year = {2026},
volume = {18},
doi = {10.52965/001c.162149}
}
EUVIMED